Results 111 to 120 of about 106,545 (283)

Imatinib and liver toxicity

BMJ Case Reports, 2018
Imatinib is a specific tyrosine kinase inhibitor which has been approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia and c-KIT (CD117)-positive gastrointestinal stromal tumours. It has been associated with hepatotoxicity ranging from abnormal liver function tests to acute liver failure along with chronic hepatitis B ...
Mohammad Inamul Haq, Joanna Nixon, Adrian J. Stanley   +2 more
openaire   +4 more sources

Development and targeted use of nilotinib in chronic myeloid leukemia

Drug Design, Development and Therapy, 2008
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour   +3 more
doaj  

Giving imatinib a hand [PDF]

The Journal of Experimental Medicine, 2008
Researchers have discovered a new a way to make the anticancer drug imatinib more effective. By suppressing the oncogene AHI-1, Zhou and colleagues were able to hold chronic myeloid leukemia (CML) in check (page 2657). Figure 1 A combination of imatinib and an AHI-1 blocker (red) killed more cells from imatinib-resistant CML patients ...
openaire   +2 more sources

Decoding Gene Expression Changes in Cerebral Tumors: Before and After Radiotherapy

Medicinal Research Reviews, EarlyView.
ABSTRACT Cerebral tumors, particularly in pediatric patients, pose a significant challenge in oncology. Radiotherapy is a crucial component of the multimodal treatment approach for these tumors. Understanding the molecular basis of these tumors, particularly their response to radiotherapy, is crucial for improving treatment outcomes and patient ...
Ahana Maitra, Morena Miciaccia, Manuela Mandorino, Domenico Armenise, Olga Maria Baldelli, Savina Ferorelli, Ludmila Papusha, Alexander Druy, Maria Grazia Perrone, Antonio Scilimati   +9 more
wiley   +1 more source

Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series

Current Problems in Cancer: Case Reports
Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease.
Deborah van de Wal, Evelyne Roets, Roos F. Bleckman, Jorn Nützinger, Birthe C. Heeres, J. Martijn Kerst, Mahmoud Mohammadi, Anna K.L. Reyners, Ingrid M.E. Desar, Astrid W. Oosten, Neeltje Steeghs, Winette T.A. van der Graaf   +11 more
doaj  

Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia [PDF]

, 2018
Quantification of BCR-ABL1 mRNA levels in peripheral blood of chronic myeloidleukemia patients is a strong indicator of response to tyrosine-kinase inhibitors (TKI)treatment.
Bianchini, Michele, Cranco, Santiago, Custidiano, María del Rosario, Foncuberta, Cecilia, Freitas, Josefina, Gutierrez, Leandro German, Koile, Daniel Isaac, Larripa, Irene Beatriz, Moiraghi, Beatriz, Mordoh, Jose, Mosqueira, Celeste, Pavlovsky, Carolina, Pérez, Mariel Ana, Ruiz, María Sol, Sanchez, María Belén, Sánchez Ávalos, Julio César Américo, Ventriglia, Verónica, Yankilevich, Patricio   +17 more
core   +1 more source

Nanosensors in Leukemia Management: Pioneering Real‐Time Biomarker Detection for Precision Oncology

Nano Select, EarlyView.
This review highlights pioneering nanosensors designed for real‐time leukemia biomarker detection, integrating advanced nanomaterials such as liposomes, polymeric nanoparticles and quantum dots. It examines electrochemical, optical and magnetic detection mechanisms, the applications across AML, ALL, CML, and CLL subtypes, and clinical translation ...
Hamed Soleimani Samarkhazan, Mohammad Navid Khaksari, Amirhossein Mirzazadeh, Mohammad Siavashi, Niloofar Pilehvari, Mohammad Hossein Mohammadi   +5 more
wiley   +1 more source

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

Haematologica, 2012
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib.
Naoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, Takashi Sugihara, Kensuke Usuki, Tatsuya Kawaguchi, Noriko Usui, Shinichiro Okamoto, Yokiko Ohe, Shigeki Ohtake, Kunio Kitamura, Masahide Yamamoto, Hirofumi Teshima, Toshiko Motoji, Toshiharu Tamaki, Kenichi Sawada, Kazuma Ohyashiki   +16 more
doaj   +1 more source

Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update [PDF]

, 2018
Despite considerable progress in treatment protocols, B-lineage acute lymphoblastic leukemia (B-ALL) displays a poor prognosis in about 15–20% of pediatric cases and about 60% of adult patients. In addition, life-long irreversible late effects from chemo-
Capitani, Silvano, Martelli, Alberto M., McCubrey, James A., Neri, Luca M., Simioni, Carolina, Vitale, Marco, Zauli, Giorgio   +6 more
core   +1 more source

Therapeutic drug monitoring of imatinib [PDF]

Revista Brasileira de Hematologia e Hemoterapia, 2011
In this issue of the Revista Brasileira de Hematologia e Hemoterapia, Martins et al.(1) are publishing an interesting review, a meta-analysis, of the clinical and analytical aspects of therapeutic drug monitoring of imatinib in chronic myeloid leukemia (CML). Imatinib, the archetype for tyrosine kinase inhibitor therapeutics, is an excellent example
openaire   +7 more sources